Logo

AstraZeneca’s Imfinzi Received the EU’s CHMP Positive opinion for the treatment of Hepatocellular Carcinoma

Share this
AstraZeneca

AstraZeneca’s Imfinzi Received the EU’s CHMP Positive opinion for the treatment of Hepatocellular Carcinoma

Shots:

  • The positive opinion was adopted for the new indication of Imfinzi (durvalumab) as 1L monotx. for the treatment of advanced or unresectable hepatocellular carcinoma was based on a P-III study (HIMALAYA)
  • The P-III (HIMALAYA) clinical trial evaluates the safety & efficacy of Imjudo (300mg) + Imfinzi (1500, q4w) vs sorafenib in unresectable HCC patients (n=1324) with no prior systemic therapy
  • Imfinzi (durvalumab) is a human PD-L1 protein and blocks PD-1 and CD80 proteins. Imfinzi in combination with Imjudo (tremelimumab) approved in unresectable HCC in the US, EU, Japan and many other countries based on the TOPAZ-1 and HIMALAYA study

Ref: European Medicines Agency | Image: AstraZeneca

*Note: This is not an original PR, this reference is taken based on European Medicines Agency website

Related News:- AstraZeneca Received NMPA Approval for Imfinzi + CT to Treat Patients with Locally Advanced/metastatic Biliary Tract Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Kritika Jha

Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions